Welcome to our dedicated page for Penumbra SEC filings (Ticker: PEN), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Penumbra, Inc. filings document the regulatory record for a NYSE-listed medical-device company focused on thrombectomy technologies for stroke, pulmonary embolism, venous thromboembolism, and acute limb ischemia. Form 8-K reports cover operating results, material-event disclosures, material agreements, capital-structure matters, and clinical or regulatory updates involving its thrombectomy portfolio.
Proxy materials describe shareholder voting matters, governance practices, compensation arrangements, and capital-structure proposals. The filing record also includes disclosures on risk factors, financial condition, executive appointments and compensatory arrangements, and the company's common stock registered under the symbol PEN on the New York Stock Exchange.
Penumbra Director Bridget O'Rourke reported a Form 4 filing disclosing the sale of 50 shares of common stock at a price of $259.78 per share on June 16, 2025. The transaction was executed under a pre-established Rule 10b5-1 trading plan, which provides a safe harbor from insider trading allegations.
Following the transaction, O'Rourke maintains beneficial ownership of 5,373 shares held directly, with a portion subject to vesting restrictions. The filing was submitted on June 28, 2025, within the required reporting timeframe.
- Transaction Type: Sale of Common Stock
- Total Transaction Value: $12,989
- Ownership Form: Direct
- Role: Director